# Cystic and Adenofibromatous Clear Cell Carcinomas of

American Journal of Surgical Pathology
33, 844-853
DOI: 10.1097/pas.0b013e31819c4271

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 261-270. | 1.4 | 22 |
| 2 | Borderline clear cell adenofibroma with extensive hemorrhagic necrosis. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 158-160. | 0.6 | 3 |
| 3 | Cystic and Adenofibromatous Clear Cell Carcinomas of the Ovary: Distinctive Tumors That Differ in Their Pathogenesis and Behavior: A Clinicopathologic Analysis of 122 Cases. Yearbook of Pathology and Laboratory Medicine, 2010, 2010, 108-110. | 0.0 | 0 |
| 4 | Precursors of endometrial and ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 1-12. | 1.4 | 29 |
| 5 | Cumulative alterations of p27<sup>Kip1</sup>â€related cellâ€cycle regulators in the development of endometriosisâ€associated ovarian clear cell adenocarcinoma. Histopathology, 2010, 56, 740-749. | 1.6 | 23 |
| 6 | Major clinical research advances in gynecologic cancer in 2010. Journal of Gynecologic Oncology, 2010, 21, 209. | 1.0 | 15 |
| 7 | DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma. Clinical Cancer Research, 2010, 16, 1997-2008. | 3.2 | 85 |
| 8 | The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. American Journal of Surgical Pathology, 2010, 34, 433-443. | 2.1 | 1,503 |
| 9 | Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma. International Journal of Molecular Sciences, 2010, 11, 5120-5128. | 1.8 | 100 |
| 10 | HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Modern Pathology, 2010, 23, 673-681. | 2.9 | 78 |
| 11 | Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. Science, 2010, 330, 228-231. | 6.0 | 1,090 |
| 12 | Nonserous Ovarian Epithelial Tumors. Surgical Pathology Clinics, 2011, 4, 397-459. | 0.7 | 8 |
| 13 | Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics, 2011, 4, 275-296. | 0.7 | 1 |
| 14 | Surface Epithelial Tumors of the Ovary. , 2011, , 679-784. | | 62 |
| 15 | Molecular pathogenesis and extraovarian origin of epithelial ovarian cancerâ€"Shifting the paradigm. Human Pathology, 2011, 42, 918-931. | 1.1 | 932 |
| 16 | Pathogenesis of Ovarian Clear Cell Adenofibroma, Atypical Proliferative (Borderline) Tumor, and Carcinoma: Clinicopathologic Features of Tumors with Endometriosis or Adenofibromatous Components Support Two Related Pathways of Tumor Development. Journal of Cancer, 2011, 2, 94-106. | 1.2 | 61 |
| 17 | Ovarian Epithelial Cancer Stem Cells. Scientific World Journal, The, 2011, 11, 1243-1269. | 0.8 | 17 |
| 18 | Rsf-1 (HBXAP) Expression is Associated With Advanced Stage and Lymph Node Metastasis in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2011, 30, 30-35. | 0.9 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Ovarian clear cell adenofibromatous tumor of borderline malignancy associated with high levels of carbohydrate antigen 19â€9. Journal of Obstetrics and Gynaecology Research, 2011, 37, 472-477. | 0.6 | 3 |
| 21 | Ovarian clear cell carcinomaâ€"bad endometriosis or bad endometrium?. Journal of Pathology, 2011, 225, 157-160. | 2.1 | 30 |
| 22 | Typing of ovarian carcinomas: an update. Diagnostic Histopathology, 2011, 17, 165-177. | 0.2 | 5 |
| 23 | Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Modern Pathology, 2011, 24, 1139-1145. | 2.9 | 29 |
| 24 | Histologic, Molecular, and Cytogenetic Features of Ovarian Cancers: Implications for Diagnosis and Treatment. Radiographics, 2011, 31, 625-646. | 1.4 | 150 |
| 25 | Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Modern Pathology, 2012, 25, 615-624. | 2.9 | 205 |
| 26 | Clear Cell Carcinomas of the Mullerian System: Does the Pathogenesis Vary Depending on Their Nuclear Grade and Their Association with Endometriosis? An Immunohistochemical Analysis. Pathology Research International, 2012, 2012, 1-6. | 1.4 | 4 |
| 27 | Clear Cell Carcinoma of the Female Genital Tract (Not Everything Is as Clear as it Seems). Advances in Anatomic Pathology, 2012, 19, 296-312. | 2.4 | 31 |
| 28 | Aberrant Expression of the Mammalian Target of Rapamycin, Hypoxia-inducible Factor-1Î±, and Glucose Transporter 1 in the Development of Ovarian Clear-cell Adenocarcinoma. International Journal of Gynecological Pathology, 2012, 31, 254-263. | 0.9 | 15 |
| 29 | Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Modern Pathology, 2012, 25, 282-288. | 2.9 | 170 |
| 30 | New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. Gynecological Endocrinology, 2012, 28, 582-586. | 0.7 | 12 |
| 31 | Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Human Pathology, 2012, 43, 2197-2206. | 1.1 | 59 |
| 32 | Ovarian Cancer: Opportunity for Targeted Therapy. Journal of Oncology, 2012, 2012, 1-9. | 0.6 | 32 |
| 33 | Ovarian Cancer is an Imported Disease: Fact or Fiction?. Current Obstetrics and Gynecology Reports, 2012, 1, 1-9. | 0.3 | 105 |
| 34 | PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 77-87. | 1.4 | 89 |
| 36 | Gynecologic Cancers. Clinics in Laboratory Medicine, 2013, 33, 911-925. | 0.7 | 3 |
| 38 | New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. BioMed Research International, 2013, 2013, 1-13. | 0.9 | 22 |
| 39 | Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms. Advances in Anatomic Pathology, 2013, 20, 45-52. | 2.4 | 98 |

| # | Article | IF | Citations |
|---|---|---|---|
| 40 | Precursors and pathogenesis of ovarian carcinoma. Pathology, 2013, 45, 229-242. | 0.3 | 128 |
| 41 | The roles of ARID1A in gynecologic cancer. Journal of Gynecologic Oncology, 2013, 24, 376. | 1.0 | 53 |
| 42 | Pathology of benign and malignant ovarian epithelial tumors. , 0, , 79-88. | | 0 |
| 44 | Pathology of the Ovary, Fallopian Tube and Peritoneum. , 2014, , . | | 3 |
| 45 | Identification of differentially methylated genes in the malignant transformation of ovarian endometriosis. Journal of Ovarian Research, 2014, 7, 73. | 1.3 | 29 |
| 46 | Clinical Characteristics of Patients in Japan with Ovarian Cancer Presumably Arising from Ovarian Endometrioma. Gynecologic and Obstetric Investigation, 2014, 77, 104-110. | 0.7 | 26 |
| 47 | Comparison of Pure and Mixed-Type Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer, 2014, 24, 1590-1596. | 1.2 | 9 |
| 48 | Pathogenesis of the Endometriosis-Related Ovarian Neoplasms. Current Obstetrics and Gynecology Reports, 2014, 3, 1-8. | 0.3 | 1 |
| 49 | Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Archives of Gynecology and Obstetrics, 2014, 289, 241-246. | 0.8 | 39 |
| 51 | Characteristics of clear cell ovarian cancer arising from endometriosis: A two center cohort study. Gynecologic Oncology, 2014, 133, 480-484. | 0.6 | 72 |
| 52 | Histoâ€genomic stratification reveals the frequent amplification/overexpression of <scp>CCNE</scp>1 and <scp>BRD</scp>4 genes in nonâ€BRCAness high grade ovarian carcinoma. International Journal of Cancer, 2015, 137, 1890-1900. | 2.3 | 48 |
| 53 | Clear Cell Adenocarcinoma Arising in an Adenomyoma of the Broad Ligament. International Journal of Surgical Pathology, 2015, 23, 140-143. | 0.4 | 10 |
| 54 | Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. Medical Molecular Morphology, 2015, 48, 146-154. | 0.4 | 6 |
| 55 | Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 2738-2745. | 0.7 | 21 |
| 56 | <scp>ARID</scp>1A expression in ovarian clear cell carcinoma with an adenofibromatous component. Histopathology, 2015, 67, 866-871. | 1.6 | 21 |
| 57 | Atlas of Clear Cell Carcinoma of the Ovary. , 2015, , . | | 2 |
| 58 | The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocrine-Related Cancer, 2015, 22, R339-R363. | 1.6 | 33 |
| 59 | Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases. Histopathology, 2015, 66, 808-815. | 1.6 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 60 | Distinct Î²-Catenin and PIK3CA Mutation Profiles in Endometriosis-Associated Ovarian Endometrioid and Clear Cell Carcinomas. American Journal of Clinical Pathology, 2015, 144, 452-463. | 0.4 | 53 |
| 61 | Transcriptional upregulation of HNF-1Î² by NF-ÎºB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Laboratory Investigation, 2015, 95, 962-972. | 1.7 | 31 |
| 62 | ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin. Experimental and Therapeutic Medicine, 2016, 12, 4067-4071. | 0.8 | 15 |
| 63 | Clear cell carcinoma of the ovary: comparison of MR findings of histological subtypes. Abdominal Radiology, 2016, 41, 2476-2483. | 1.0 | 11 |
| 64 | Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. Molecular and Clinical Oncology, 2016, 5, 395-401. | 0.4 | 13 |
| 65 | ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncology Reports, 2016, 35, 607-613. | 1.2 | 136 |
| 66 | Precancerous Lesions of the Gynecologic Tract. , 2016, , . | | 2 |
| 69 | Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000â€“2013. Annals of Oncology, 2017, 28, 2985-2993. | 0.6 | 67 |
| 70 | Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors. Comprehensive Gynecology and Obstetrics, 2017, , 37-56. | 0.0 | 1 |
| 71 | Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. Gynecologic Oncology, 2017, 146, 609-614. | 0.6 | 15 |
| 72 | L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecologic Oncology, 2017, 146, 615-622. | 0.6 | 12 |
| 73 | Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 761-778. | 1.3 | 41 |
| 74 | Epidemiology of ovarian cancer: a review. Cancer Biology and Medicine, 2017, 14, 9-32. | 1.4 | 981 |
| 75 | Evaluation of childhood pancreas solid pseudopapillary tumors. Ä°stanbul Kuzey Klinikleri, 2017, 5, 207-210. | 0.1 | 3 |
| 76 | Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma. American Journal of Clinical Pathology, 2018, 149, 352-361. | 0.4 | 6 |
| 77 | Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?. Archives of Gynecology and Obstetrics, 2018, 297, 1005-1013. | 0.8 | 7 |
| 78 | Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from highâ€grade serous carcinoma. Apmis, 2018, 126, 45-55. | 0.9 | 28 |
| 79 | Endometriosis-associated ovarian neoplasia. Pathology, 2018, 50, 190-204. | 0.3 | 113 |

| # | Article | IF | Citations |
|---|---|---|---|
| 80 | When Is â€œType Iâ€•Ovarian Cancer Not â€œType Iâ€? Indications of an Out-Dated Dichotomy. Frontiers in Oncology, 2018, 8, 654. | 1.3 | 29 |
| 81 | Frontiers in the Pathology and Pathogenesis of Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 915-928. | 0.9 | 12 |
| 82 | Epithelial Tumors of the Ovary. , 2018, , 1-128. | | 0 |
| 83 | The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2018, , 865-948. | | 1 |
| 84 | Gynecologic Cancers. Clinics in Laboratory Medicine, 2018, 38, 421-438. | 0.7 | 9 |
| 85 | Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma. Ultrasound in Obstetrics and Gynecology, 2018, 52, 792-800. | 0.9 | 36 |
| 86 | Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Human Pathology, 2018, 80, 11-27. | 1.1 | 170 |
| 87 | Origins based clinical and molecular complexities of epithelial ovarian cancer. International Journal of Biological Macromolecules, 2018, 118, 1326-1345. | 3.6 | 21 |
| 88 | Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Medicine, 2019, 16, e1002893. | 3.9 | 78 |
| 89 | Ovarian Endometrioid and Clear-Cell Tumors. , 2019, , 173-201. | | 0 |
| 90 | Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary. Surgical Pathology Clinics, 2019, 12, 529-564. | 0.7 | 51 |
| 91 | Epithelial Tumors of the Ovary. , 2019, , 841-966. | | 10 |
| 92 | Gynecological neoplasms associated with paraneoplastic hypercalcemia. Seminars in Diagnostic Pathology, 2019, 36, 246-259. | 1.0 | 10 |
| 93 | Mitochondrial translocation of estrogen receptor Î² affords resistance to oxidative insult-induced apoptosis and contributes to the pathogenesis of endometriosis. Free Radical Biology and Medicine, 2019, 134, 359-373. | 1.3 | 30 |
| 94 | High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International Journal of Molecular Sciences, 2019, 20, 952. | 1.8 | 381 |
| 95 | Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 631-636. | 0.6 | 1 |
| 96 | Gynecological Pathology. , 2020, , 1049-1521. | | 0 |
| 97 | What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics, 2021, 11, 697. | 1.3 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 98 | Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma. Histopathology, 2021, 79, 758-767. | 1.6 | 2 |
| 99 | Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study. Archives of Gynecology and Obstetrics, 2021, , 1. | 0.8 | 1 |
| 100 | Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecologic Oncology, 2021, 162, 741-750. | 0.6 | 49 |
| 101 | Clear Cell Carcinoma of the Ovary. , 2014, , 259-271. | | 3 |
| 102 | Chemoresistance, Dormancy and Recurrence in Platinum Drug Therapy of Ovarian Cancers. , 2014, , 79-97. | | 1 |
| 103 | The association between endometriosis and survival outcomes of ovarian cancer: Evidence-based on a meta-analysis. Nigerian Journal of Clinical Practice, 2015, 18, 577. | 0.2 | 5 |
| 104 | Primary Ovarian Clear Cell Adenofibroma of Borderline Malignancy. Oman Medical Journal, 2012, 27, e031. | 0.3 | 4 |
| 105 | Endometriosis-Associated Ovarian Cancer: The Role of Oxidative Stress. , 0, , . | | 1 |
| 106 | A case of borderline clear cell fibroadenoma. Korean Journal of Obstetrics and Gynecology, 2010, 53, 737. | 0.1 | 0 |
| 107 | Ovarian Clear Cell Carcinoma. , 2011, , 83-90. | | 1 |
| 108 | Pathology of Clear Cell Tumors. , 2011, , 91-104. | | 0 |
| 109 | The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2011, , 818-895. | | 2 |
| 111 | Endometrioid Ovarian Carcinomas. , 2014, , 239-258. | | 0 |
| 114 | Epithelial Tumors of the Ovary. , 2018, , 1-128. | | 0 |
| 116 | Clinically Suspected Dysgerminoma Sent for Frozen Section Confirmation. AJSP Review and Reports, 2020, 25, 284-294. | 0.0 | 0 |
| 117 | Oophorectomy or ovarian conservation at the time of hysterectomy for benign disease. The Obstetrician and Gynaecologist, 2022, 24, 131-136. | 0.2 | 2 |
| 118 | Ovary and fallopian tube. , 0, , 2726-2822. | | 0 |
| 119 | Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. International Journal of Gynecological Cancer, 2010, 20, 1490-7. | 1.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 120 | Frozen section diagnosis of ovarian epithelial tumours: a practical guide for pathologists. Diagnostic Histopathology, 2022, , . | 0.2 | 0 |
| 121 | Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction. , 2023, 40, . | | 11 |
| 122 | Clear Cell Tumors. , 2023, , 73-100. | | 0 |
| 124 | Clear Cell Carcinoma of the Ovary. , 2023, , 457-478. | | 0 |
| 126 | Ovarian Endometrioid and Clear-Cell Tumors. , 2024, , 1-32. | | 0 |